Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol

Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a...

Descripción completa

Detalles Bibliográficos
Autores: Salvador, F, Lucas-Dato, A, Roure, S, Arsuaga, M, Perez-Jacoiste, A, Garcia-Rodriguez, M, Perez-Molina, JA, Buonfrate, D, Saugar, JM, Molina, I
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p10736
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/10736
Access Level:acceso abierto
Palabra clave:Strongyloides stercoralis
immunosuppression
ivermectin
PCR
population pharmacokinetics
id ES_052943ff8ea0eebd36ba6f8f73fbe88c
oai_identifier_str oai:fisabio.fundanetsuite.com:p10736
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study ProtocolSalvador, FLucas-Dato, ARoure, SArsuaga, MPerez-Jacoiste, AGarcia-Rodriguez, MPerez-Molina, JABuonfrate, DSaugar, JMMolina, IStrongyloides stercoralisimmunosuppressionivermectinPCRpopulation pharmacokineticsStrongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.MDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/10736PathogensISSN: 20760817reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p107362026-06-11T12:45:17Z
dc.title.none.fl_str_mv Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
spellingShingle Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
Salvador, F
Strongyloides stercoralis
immunosuppression
ivermectin
PCR
population pharmacokinetics
title_short Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_full Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_fullStr Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_full_unstemmed Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_sort Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
dc.creator.none.fl_str_mv Salvador, F
Lucas-Dato, A
Roure, S
Arsuaga, M
Perez-Jacoiste, A
Garcia-Rodriguez, M
Perez-Molina, JA
Buonfrate, D
Saugar, JM
Molina, I
author Salvador, F
author_facet Salvador, F
Lucas-Dato, A
Roure, S
Arsuaga, M
Perez-Jacoiste, A
Garcia-Rodriguez, M
Perez-Molina, JA
Buonfrate, D
Saugar, JM
Molina, I
author_role author
author2 Lucas-Dato, A
Roure, S
Arsuaga, M
Perez-Jacoiste, A
Garcia-Rodriguez, M
Perez-Molina, JA
Buonfrate, D
Saugar, JM
Molina, I
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Strongyloides stercoralis
immunosuppression
ivermectin
PCR
population pharmacokinetics
topic Strongyloides stercoralis
immunosuppression
ivermectin
PCR
population pharmacokinetics
description Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/10736
url https://fisabio.portalinvestigacion.com/publicaciones/10736
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Pathogens
ISSN: 20760817
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402837679603712
score 15,811543

Similares en LA Referencia